and who cares takes them to phase 2 and non dilutive opportunities with the US defence force on a first in class drug that has showed huge results and will be cleared safe in humans for three unmet indications with a 60 billion dollar market with no competition:
Either way in 24 months will be a billion dollar plus company and first stop north of a 100 million dollars. 13 million market will still end up multiples short term and still bought more yesterday
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)